MB, Levis & Associates’s DexCom DXCM Stock Holding History

MB, Levis & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.15K	Hold	32	–	–	﹤0.01%	232
2026 Q1	$2.01K	Hold	32	–	–	﹤0.01%	210
2025 Q4	$2.12K	Hold	32	–	–	﹤0.01%	219
2025 Q3	$2.15K	Hold	32	–	–	﹤0.01%	217
2025 Q2	$2.79K	Hold	32	–	–	﹤0.01%	236
2025 Q1	$2.19K	Hold	32	–	–	﹤0.01%	250
2024 Q4	$2.49K	Hold	32	–	–	﹤0.01%	253
2024 Q3	$2.15K	Hold	32	–	–	﹤0.01%	258
2024 Q2	$3.63K	Hold	32	–	–	﹤0.01%	232
2024 Q1	$4.44K	Hold	32	–	–	﹤0.01%	224
2023 Q4	$3.97K	Hold	32	–	–	﹤0.01%	223
2023 Q3	$2.99K	Hold	32	–	–	﹤0.01%	233
2023 Q2	$4.11K	Hold	32	–	–	﹤0.01%	227
2023 Q1	$3.72K	Hold	32	–	–	﹤0.01%	231
2022 Q4	$3.62K	Buy	+32	New	+$3.51K	﹤0.01%	214

Other funds holding DXCM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

MB, Levis & Associates's DXCM Position: Q2 2026 in Review

MB, Levis & Associates held its DexCom (DXCM) position steady in Q2 2026 at 32 shares worth $2.15K. The position accounts for ﹤0.01% of the portfolio, ranked #232.

MB, Levis & Associates first reported a position in DXCM in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.44K in Q1 2024. 974 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

MB, Levis & Associates held 32 shares of DexCom worth $2.15K as of Q2 2026.
MB, Levis & Associates left its DexCom share count unchanged in Q2 2026.
DexCom made up ﹤0.01% of MB, Levis & Associates's portfolio in Q2 2026, its #232 holding.
MB, Levis & Associates first reported a position in DexCom in Q4 2022 and has held it in 15 quarters since.
MB, Levis & Associates's DexCom position peaked at $4.44K in Q1 2024.
974 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on MB, Levis & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.